EA202092030A1 - Офтальмологическая композиция, включающая диквафозол и катионный полимер - Google Patents

Офтальмологическая композиция, включающая диквафозол и катионный полимер

Info

Publication number
EA202092030A1
EA202092030A1 EA202092030A EA202092030A EA202092030A1 EA 202092030 A1 EA202092030 A1 EA 202092030A1 EA 202092030 A EA202092030 A EA 202092030A EA 202092030 A EA202092030 A EA 202092030A EA 202092030 A1 EA202092030 A1 EA 202092030A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cationic
copolymer
hydrolyzed
polymer
ophthalmic composition
Prior art date
Application number
EA202092030A
Other languages
English (en)
Russian (ru)
Inventor
Киохеи Такахаси
Хироюки Асада
Асука Камимура
Кендзи Морисима
Юсуке Момокава
Кенити Эндо
Original Assignee
Сантен Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сантен Фармасьютикал Ко., Лтд. filed Critical Сантен Фармасьютикал Ко., Лтд.
Publication of EA202092030A1 publication Critical patent/EA202092030A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
EA202092030A 2018-02-28 2019-02-27 Офтальмологическая композиция, включающая диквафозол и катионный полимер EA202092030A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018035578 2018-02-28
PCT/JP2019/007542 WO2019168023A1 (ja) 2018-02-28 2019-02-27 ジクアホソルおよびカチオン性ポリマーを含有する眼科用組成物

Publications (1)

Publication Number Publication Date
EA202092030A1 true EA202092030A1 (ru) 2020-11-16

Family

ID=67806273

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092030A EA202092030A1 (ru) 2018-02-28 2019-02-27 Офтальмологическая композиция, включающая диквафозол и катионный полимер

Country Status (14)

Country Link
US (1) US20210000844A1 (enExample)
EP (1) EP3760207A4 (enExample)
JP (4) JP6716800B2 (enExample)
KR (3) KR102796051B1 (enExample)
CN (2) CN117137866A (enExample)
BR (1) BR112020017661A2 (enExample)
CA (1) CA3091700A1 (enExample)
EA (1) EA202092030A1 (enExample)
MX (2) MX2020008925A (enExample)
PH (1) PH12020551313B1 (enExample)
SG (1) SG11202007977RA (enExample)
TW (3) TWI898399B (enExample)
UA (1) UA129517C2 (enExample)
WO (1) WO2019168023A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020017661A2 (pt) * 2018-02-28 2020-12-22 Santen Pharmaceutical Co., Ltd. Composição oftálmica compreendendo diquafosol e polímero catiônico
JP7526718B2 (ja) * 2019-02-27 2024-08-01 参天製薬株式会社 ジクアホソルまたはその塩、ビニル系高分子およびセルロース系高分子を含有する眼科用組成物
TWI848171B (zh) * 2019-08-27 2024-07-11 日商參天製藥股份有限公司 含有迪夸弗索(diquafosol)或其鹽、及聚乙烯吡咯烷酮之水性眼科用組合物
KR102365008B1 (ko) * 2020-06-23 2022-02-23 주식회사태준제약 디쿠아포솔을 포함하는 점안 조성물
JP7230169B2 (ja) * 2020-12-25 2023-02-28 参天製薬株式会社 ジクアホソルまたはその塩、銀塩およびイオン性等張化剤を含有する水性点眼液
CN113712910A (zh) * 2021-08-05 2021-11-30 广州市桐晖药业有限公司 一种滴眼液及其制备方法
KR102794468B1 (ko) 2022-04-04 2025-04-14 서울대학교산학협력단 감미 억제용 조성물 및 식품의 감미 억제 방법
KR20250038935A (ko) * 2023-09-13 2025-03-20 루다큐어 주식회사 8-옥소-2'-데옥시구아노신 또는 이의 약학적으로 허용가능한 염을 포함하는 수용액 형태의 점안제
KR20250160050A (ko) 2024-05-03 2025-11-11 삼천당제약주식회사 물리화학적 특성이 개선된 안구건조증 예방 또는 치료용 약학 조성물
CN119970633A (zh) * 2025-03-26 2025-05-13 苏州乐珠制药有限公司 一种地夸磷索钠滴眼液及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01294620A (ja) 1988-05-19 1989-11-28 Kissei Pharmaceut Co Ltd 水溶液製剤およびその製造方法
US5358706A (en) * 1992-09-30 1994-10-25 Union Carbide Chemicals & Plastics Technology Corporation Muco-adhesive polymers
US5422116A (en) * 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
JP3155689B2 (ja) * 1995-08-10 2001-04-16 昭和薬品化工株式会社 消炎点眼剤
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
DE69822482T2 (de) 1997-07-25 2005-03-03 Inspire Pharmaceuticals, Inc. Salze von di(uridine 5'-tetraphosphate), verfahren zur herstellung und verwendungen davon
JP2001294620A (ja) 2000-04-11 2001-10-23 Showa Denko Kk プラスチックレンズ材料、該材料の製造方法、プラスチックレンズ用組成物、該組成物を硬化してなるプラスチックレンズ、及び該プラスチックレンズの製造方法
BR0111297A (pt) * 2000-05-30 2004-01-06 Santen Pharmaceutical Co Ltd Promotor de migração epitelial corneana
KR101389301B1 (ko) * 2005-02-14 2014-04-25 존슨 앤드 존슨 비젼 케어, 인코포레이티드 안과용 렌즈의 제조방법 및 안과용 장치
JP4515960B2 (ja) 2005-05-19 2010-08-04 株式会社資生堂 整髪料洗浄剤及びその使用方法
KR100870104B1 (ko) * 2005-11-28 2008-11-26 주식회사 머젠스 안구건조증 치료 및 예방용 조성물
EP2214660A2 (en) * 2007-10-12 2010-08-11 Resolvyx Pharmaceuticals, Inc. Omega-3 fatty acids, hydroxy polyunsaturated fatty acids, lipoxin compounds, or oxylipin compounds for the treatment of ophthalmic conditions
KR20100133980A (ko) * 2008-03-07 2010-12-22 썬 파마 어드밴스트 리서치 컴패니 리미티드 안약 조성물
BR112013016008B1 (pt) * 2010-12-28 2021-06-29 Santen Pharmaceutical Co., Ltd Solução oftálmica compreendendo diquafosol, método para a produção da mesma, e método para a inibição da formação de precipitado insolúvel
ES2702575T3 (es) * 2012-03-26 2019-03-04 Santen Pharmaceutical Co Ltd Solución oftálmica que comprende diquafosol
PL3139903T3 (pl) * 2014-05-07 2019-12-31 Croma-Pharma Gesellschaft M.B.H. Wodny roztwór oftalmiczny i sposób leczenia zespołu suchego oka
US20170105934A1 (en) * 2014-06-10 2017-04-20 Rohto Pharmaceutical Co., Ltd. Aqueous ophthalmic composition
KR102330736B1 (ko) * 2014-12-25 2021-11-23 산텐 세이야꾸 가부시키가이샤 수성 점안액
KR101587385B1 (ko) 2015-07-29 2016-01-21 국제약품공업주식회사 사이클로스포린 함유 무자극성의 안약조성물 및 편리한 제조방법
TW201722419A (zh) * 2015-08-24 2017-07-01 參天製藥股份有限公司 眼科用膜製劑
DK3266446T3 (en) * 2016-07-07 2019-02-11 Salvat Lab Sa Eye preparation comprising castor oil and medium chain triglyceride
CN106772747B (zh) * 2016-12-26 2022-10-18 深圳市光科全息技术有限公司 一种光学膜及其制作方法
AU2018257301B2 (en) * 2017-04-25 2019-10-31 Wakamoto Pharmaceutical Co., Ltd. Thermogelling artificial tears
JP6582029B2 (ja) * 2017-10-03 2019-09-25 株式会社メニコン 眼科用組成液及びその使用方法
BR112020017661A2 (pt) * 2018-02-28 2020-12-22 Santen Pharmaceutical Co., Ltd. Composição oftálmica compreendendo diquafosol e polímero catiônico
CN108853016A (zh) * 2018-09-26 2018-11-23 广州大光制药有限公司 一种地夸磷索钠滴眼液及其制备方法
JP7526718B2 (ja) * 2019-02-27 2024-08-01 参天製薬株式会社 ジクアホソルまたはその塩、ビニル系高分子およびセルロース系高分子を含有する眼科用組成物
TWI848171B (zh) * 2019-08-27 2024-07-11 日商參天製藥股份有限公司 含有迪夸弗索(diquafosol)或其鹽、及聚乙烯吡咯烷酮之水性眼科用組合物

Also Published As

Publication number Publication date
WO2019168023A1 (ja) 2019-09-06
MX2022014791A (es) 2023-01-16
PH12020551313A1 (en) 2021-09-06
EP3760207A1 (en) 2021-01-06
KR20250053220A (ko) 2025-04-21
KR102472773B1 (ko) 2022-11-30
EP3760207A4 (en) 2023-10-04
JP2022136152A (ja) 2022-09-15
CA3091700A1 (en) 2019-09-06
UA129517C2 (uk) 2025-05-21
TWI833406B (zh) 2024-02-21
TWI898399B (zh) 2025-09-21
JP2020138980A (ja) 2020-09-03
TW202306572A (zh) 2023-02-16
TW202000212A (zh) 2020-01-01
JP2024045506A (ja) 2024-04-02
KR20220163519A (ko) 2022-12-09
KR102796051B1 (ko) 2025-04-14
JPWO2019168023A1 (ja) 2020-05-28
TW202423451A (zh) 2024-06-16
PH12020551313B1 (en) 2024-02-28
BR112020017661A2 (pt) 2020-12-22
TWI781296B (zh) 2022-10-21
JP7297718B2 (ja) 2023-06-26
CN117137866A (zh) 2023-12-01
JP7472202B2 (ja) 2024-04-22
US20210000844A1 (en) 2021-01-07
KR20200127002A (ko) 2020-11-09
MX2020008925A (es) 2020-10-01
SG11202007977RA (en) 2020-09-29
CN111757742A (zh) 2020-10-09
CN111757742B (zh) 2023-09-26
JP6716800B2 (ja) 2020-07-01

Similar Documents

Publication Publication Date Title
EA202092030A1 (ru) Офтальмологическая композиция, включающая диквафозол и катионный полимер
ZA202501799B (en) Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications
BR112018072343A2 (pt) método de determinação de um filtro para uma lente oftálmica em função de uma grandeza representativa de uma sensibilidade dinâmica do olho de um portador a uma variação de um fluxo luminoso
CL2018002825A1 (es) Vacuna contra vrs
EA202191355A1 (ru) Стабилизированные f-белки rsv до слияния
BR112019000178A2 (pt) hidrogéis de silicone compreendendo n-alquil metacrilamidas e lentes de contato produzidas a partir dos mesmos
BR112018006309A2 (pt) camada implantável que compreende fibras plasticamente deformadas
BR112019000236A2 (pt) hidrogéis de silicone compreendendo poliamidas
EA202092718A1 (ru) Композиции для контроля патогенов и пути их применения
WO2004004757A8 (en) Treatment for eye disorder
FR3052977B1 (fr) Composition comprenant au moins un polymere acrylate et au moins une silicone choisie parmi les silicones fonctionalisees par au moins un groupement mercapto ou thiol
BR112017018491A2 (pt) hidrolisados de proteína à base de leite e composições produzidas a partir dos mesmos
EP3515444A4 (en) COMPOSITION FOR TREATING EYE DISEASES AND METHOD FOR USE AND PRODUCTION
BR112019006346A2 (pt) composições cosméticas para os cabelos e métodos para o tratamento dos cabelos e para conferir aos cabelos um ou mais efeitos de cuidado dos cabelos
EA202191212A1 (ru) Композиции и способы для обработки биопленок без индуцирования резистентности к противомикробным препаратам
MY197057A (en) Method for producing silicone hydrogel contact lenses
BR112015028726A2 (pt) sistema e método para programar uma lente oftálmica energizada
JOP20210300A1 (ar) أجسام مضادة مضادة لسيما 3أ واستخداماتها في علاج أمراض العين أو البصر
PT3660545T (pt) Composição de hidrogel de silicone, lente de hidrogel de silicone, e método de fabrico de lente de hidrogel de silicone
BR112015029954A2 (pt) composição e processo para tratar as fibras queratínicas
MX393880B (es) Co-cristales de compuestos de glicina sustituida y usos de los mismos.
BR0204921A (pt) Uso de silicones aminados particulares em pré- ou pós-tratamento de descoloração de fibras queratìnicas e processo de descoloração das mesmas
EP3829489A4 (en) EYE SURGICAL INJECTOR SYSTEM
TH2001004832A (th) องค์ประกอบสำหรับหยอดตาที่ประกอบรวมด้วยไดควาโฟซอลและพอลิเมอร์ประจุบวก
CO2021015337A2 (es) Métodos y composiciones que comprenden variantes de la proteína a de estafilococos (spa)